Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Macrolide antibiotics Stories

2012-12-19 08:25:13

CHAPEL HILL, N.C., Dec. 19, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its global Phase 3 clinical trial of orally-administered solithromycin, the company's fluoroketolide antibiotic candidate, in patients with community-acquired bacterial pneumonia (CABP). The Phase 3 study is a...

2012-10-17 07:27:02

SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data show continued differentiation of the company's fourth-generation macrolide/fluoroketolide, solithromycin, from currently available macrolides. The data will be presented at the IDWeek 2012(TM) conference on Oct. 17- 21 in San Diego. In one...

2012-10-08 07:24:08

CHAPEL HILL, N.C., Oct. 8, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma...

2012-09-07 02:23:53

CHAPEL HILL, N.C., Sept. 7, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Sept. 9 to 12. The data will further delineate the clinical profile and activity spectrum of solithromycin, the company's...

2012-06-26 23:02:39

Bernstein Liebhard LLP reports that Pfizer is reviewing Zithromax adverse effects in light of a study alleging a link between the antibiotic to Zithromax heart problems such as arrhythmia and sudden death. New York, New York (PRWEB) June 26, 2012 Bernstein Liebhard LLP, a New York law firm nationally recognized for its consumer protection and mass tort practices, reports that Pfizer is conducting a review of Zithromax adverse effects in response to a study concerning Zithromax heart...

2012-06-12 02:26:12

CHAPEL HILL, N.C., June 12, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP) today announced the dosing of the first two patients enrolled in a Phase 2 clinical trial to evaluate the efficacy, safety and tolerability of solithromycin in the treatment of uncomplicated urogenital gonococcal infections. The Phase 2 clinical trial is an open-label, single-center study of 30 patients with clinically-proven uncomplicated gonorrhea that will be treated with a single 1,200 mg oral dose of...

2012-05-17 11:02:46

Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a "Z-pack." The study found a 2.5-fold higher risk of death from cardiovascular death in the first five days of taking azithromycin when compared with another common antibiotic or no antibiotics at all. Wayne A. Ray, Ph.D., professor of Preventive Medicine, and C. Michael Stein, M.B.Ch.B., the Dan May Chair in Medicine and professor of Pharmacology, collaborated on the...

Popular Antibiotic May Be Responsible For Sudden Cardiac Death
2012-05-17 11:02:26

Lawrence LeBlond for RedOrbit.com Azithromycin, a common antibiotic used for treatment of bronchitis, pneumonia, and sexually transmitted diseases (STDs), appears to also boost the risk of sudden cardiac death when compared with no antibiotic treatment, according to a US study on Wednesday. Azithromycin has been available worldwide since the 1980s, but the new study, published in the New England Journal of Medicine (New England Journal of Medicine), is the first to document serious...

2012-03-30 18:20:08

CHAPEL HILL, N.C., March 31, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae. "Solithromycin is our...

2011-11-09 05:21:00

CHENGDU, China, Nov. 9, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced that following the initial phase of operation, the Jiangchuan Macrolide Facility (JCM) has passed the internal quality assessment for its first batch of...